4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Janux Therapeutics, Inc. (JANX) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 108 employees. Its market capitalization is roughly $992 million. In the fiscal year ended 2025-12-31, JANX reported $10M in revenue and ($114M) in net income.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Interactive charts & full statements → Open the JANX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $10M | $11M | $8M | $9M | — |
| Operating Income (EBIT) | ($158M) | ($99M) | ($73M) | ($67M) | — |
| Net Income | ($114M) | ($69M) | ($58M) | ($63M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $4M | $0M | $10M | $0M | $0M |
| Operating Income (EBIT) | ($34M) | ($42M) | ($35M) | ($45M) | ($35M) |
| Net Income | ($24M) | ($32M) | ($24M) | ($34M) | ($24M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.0B | $1.1B | $380M | $364M | — |
| Total Liabilities | $45M | $39M | $36M | $43M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive JANX viewer.
About TickerBase · Data methodology & sources